Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
BMC Mol Cell Biol. 2022 Feb 24;23(1):11. doi: 10.1186/s12860-022-00410-z.
To circumvent some pitfalls related to acute status, chronic model of asthma is conceived to be more suitable approach to guarantee the conditions which are similar to human pulmonary disease. Here, possible therapeutic mechanisms were monitored by which c-kit bone marrow cells can attenuate vascular inflammation in rat model of chronic asthma.
Data revealed c-Kit cells could significantly reduce pathological injures in asthmatic rats via modulating the expression of IL-4, INF-γ, ICAM-1 and VCAM-1 in lung tissues and TNF-α, IL-1β and NO levels in BALF (p < 0.001 to p < 0.05). Besides, c-Kit cells reduced increased levels of VCAM-1 evaluated by immunohistochemistry staining. In contrast to c-Kit cells, c-Kit cells could not exert beneficial effects in the asthmatic conditions.
Overall, we found that systemic administration of C-kit positive cells can diminish pulmonary and vascular inflammation of chronic asthmatic changes in a rat model. These cells are eligible to suppress inflammation and nitrosative stress in lung tissue coincides with the reduction of pathological changes. These data indicate that C-kit positive cells be used as an alternative cell source for the amelioration of asthmatic changes.
为了规避与急性状态相关的一些陷阱，人们设想慢性哮喘模型是一种更合适的方法，以保证与人类肺部疾病相似的条件。在这里，通过监测 c-kit 骨髓细胞可能减轻慢性哮喘大鼠血管炎症的可能治疗机制。
数据显示，c-Kit 细胞通过调节肺组织中 IL-4、INF-γ、ICAM-1 和 VCAM-1 的表达以及 BALF 中 TNF-α、IL-1β 和 NO 水平，可显著减轻哮喘大鼠的病理损伤（p<0.001 至 p<0.05）。此外，c-Kit 细胞减少了免疫组织化学染色评估的 VCAM-1 水平升高。与 c-Kit 细胞相反，c-Kit 细胞在哮喘条件下不能发挥有益作用。
总之，我们发现系统给予 C-kit 阳性细胞可减轻大鼠慢性哮喘模型中的肺和血管炎症变化。这些细胞有资格抑制肺组织中的炎症和硝化应激，同时减少病理变化。这些数据表明，C-kit 阳性细胞可作为改善哮喘变化的替代细胞来源。
